Healthcare Analysts discuss key considerations ahead of PTC Therapeutics’ top-line data from the Phase III APHENITY trial of PTC923 on an Analyst/Industry conference call to be held on April 28 at 10 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PTCT: